abbv-cls-7262
Small moleculeexperimental
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Sep 22, 2021 (NCT04948645)
Timeline
Indications
Mechanism of action
EIF2B3 activator
Chemistry & pharmacology
Loading structure…
SMILES
O=C(COc1ccc(Cl)c(F)c1)NC12CCC(NC(=O)COc3ccc(Cl)c(F)c3)(CC1)[C@@H](OCOP(=O)(O)O)C2- Mol. weight
- 639.37 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5315045 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07300397 | N/A | Dec 3, 2025 | McGill University |
| NCT07272525 | Early Phase 1 (Phase 1) | Nov 14, 2024 | McGill University |
| NCT06618118 | Phase 1 | Oct 23, 2024 | AbbVie |
| NCT06425003 | Phase 1 | May 21, 2024 | AbbVie, Calico Life Sciences LLC |
| NCT06310876 | Phase 1 | Mar 14, 2024 | AbbVie, Calico Life Sciences LLC |
| NCT06145607 | Phase 1 | Dec 31, 2023 | AbbVie, Calico Life Sciences LLC |
| NCT05763459 | Phase 1 | Mar 24, 2023 | AbbVie, Calico Life Sciences LLC |
| NCT05740813 | Phase 2/Phase 3 (Phase 3) | Mar 23, 2023 | Calico Life Sciences LLC, Harvard University |
| NCT05757141 | Phase 1 | Mar 13, 2023 | AbbVie, Calico Life Sciences LLC |
| NCT04948645 | Phase 1 | Sep 22, 2021 | AbbVie, Calico Life Sciences LLC |
| NCT06594016 | N/A | — | AbbVie |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 8 | 2 | 2 | 2021 |
| Calico Life Sciences LLC | For profit | 7 | 6 | 2 | 2021 |
| McGill University | Academic/Hospital | 2 | 2 | 2 | 2024 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1